|1.||Zhang, Hai-Ping: 1 article (07/2014)|
|2.||Kong, Bin: 1 article (07/2014)|
|3.||Hasim, Ayshamgul: 1 article (07/2014)|
|4.||Ma, Hong: 1 article (07/2014)|
|5.||Mamtimin, Batur: 1 article (07/2014)|
|6.||Sheyhidin, Ilyar: 1 article (07/2014)|
12/28/1993 - "A significant increase in cytotoxicity of the prodrug epi-glu was shown when the in vitro cultured cancer cells were pretreated with these immuno-enzymosomes."
09/01/1992 - "Epi (IC50 of 0.003-0.2 microM) was 100-1,000 times more toxic than Epi-glu (IC50 of greater than 20 microM), when cancer cells were exposed for 4 or 24 h to the drugs. "
09/01/1992 - "Epi-glu was stable in human blood and was not converted into Epi by A2780, MCF-7, or OVCAR-3 cancer cells, despite the presence of intracellular GUS. "
09/01/1992 - "A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer."
01/01/1994 - "We compared two prodrugs, epirubicin-glucuronide (Epi-glu) and doxorubicin-spacer-glucuronide (Dox-sp-glu), for their cytotoxicity on activation by a monoclonal antibody-enzyme conjugate bound to tumor cells. "
|2.||Ovarian Neoplasms (Ovarian Cancer)
|3.||Neoplasm Metastasis (Metastasis)
|1.||epidoxorubicin glucuronide (E-glu)